Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

TUESDAY, Sept. 18, 2018 -- In patients with transthyretin amyloid cardiomyopathy, treatment with tafamidis reduces all-cause mortality and cardiovascular-related hospitalizations versus placebo, according to a study published in the Sept. 13 issue...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news